Smith Anglin Financial LLC Makes New $108,000 Investment in Teladoc Health, Inc. (NYSE:TDOC)

Smith Anglin Financial LLC purchased a new position in Teladoc Health, Inc. (NYSE:TDOC) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,898 shares of the health services provider’s stock, valued at approximately $108,000.

A number of other large investors have also added to or reduced their stakes in TDOC. Point72 Asset Management L.P. boosted its stake in shares of Teladoc Health by 57.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 8,366,295 shares of the health services provider’s stock valued at $76,803,000 after purchasing an additional 3,063,172 shares in the last quarter. Rubric Capital Management LP bought a new stake in shares of Teladoc Health during the 2nd quarter valued at about $45,267,000. Clearline Capital LP boosted its stake in shares of Teladoc Health by 395.6% during the 2nd quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after purchasing an additional 3,483,665 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Teladoc Health by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 3,925,167 shares of the health services provider’s stock valued at $36,042,000 after purchasing an additional 56,864 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Teladoc Health during the 3rd quarter valued at about $15,801,000. Institutional investors own 76.82% of the company’s stock.

Analyst Ratings Changes

TDOC has been the subject of several recent research reports. TD Cowen lowered their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “hold” rating for the company in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft upped their price objective on Teladoc Health from $10.00 to $12.00 and gave the company a “hold” rating in a research report on Friday, November 1st. Barclays boosted their price target on Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. The Goldman Sachs Group initiated coverage on Teladoc Health in a research report on Friday, November 15th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, Piper Sandler reiterated an “overweight” rating and issued a $13.00 price objective (up from $11.00) on shares of Teladoc Health in a report on Wednesday, December 4th. Fourteen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Teladoc Health has a consensus rating of “Hold” and a consensus target price of $12.24.

Insiders Place Their Bets

In other Teladoc Health news, insider Carlos Nueno sold 2,389 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $11.93, for a total value of $28,500.77. Following the completion of the transaction, the insider now directly owns 2,890 shares in the company, valued at $34,477.70. This represents a 45.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.95% of the company’s stock.

Teladoc Health Price Performance

Shares of TDOC stock opened at $9.36 on Thursday. Teladoc Health, Inc. has a 12 month low of $6.76 and a 12 month high of $21.74. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. The company has a 50 day simple moving average of $9.99 and a two-hundred day simple moving average of $9.02.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. The business had revenue of $640.51 million during the quarter, compared to analysts’ expectations of $630.50 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. On average, analysts expect that Teladoc Health, Inc. will post -1.16 EPS for the current fiscal year.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.